Clinical trial

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-09-03

PhasePHASE3

Study timeline

Study start (actual)2013-09-03Date precision: day

Registry last updated2018-11-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIV-1unresolved

HIV Infectionsunresolved

Acquired Immunodeficiency Syndromeunresolved

Interventions

E/C/F/TAFDRUG

DRVDRUG

Baseline DRV- containing ARV regimenDRUG

Sponsors & collaborators

Gilead Scienceslead sponsor

Mapped research locations

PhiladelphiaPennsylvania, United States3 New YorkNew York, United States2 HoustonTexas, United States2 BostonMassachusetts, United States2 ChicagoIllinois, United States2 AtlantaGeorgia, United States2 TampaFlorida, United States2 OrlandoFlorida, United States2 Fort LauderdaleFlorida, United States2 Los AngelesCalifornia, United States1 DallasTexas, United States1 St LouisMissouri, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01968551 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.